The EEA1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line. This product enables targeted disruption of the EEA1 gene (Early Endosome Antigen 1), generating a heterogeneous pool of cells with loss-of-function mutations at the target locus. The polyclonal format provides a powerful model system for studying endocytic trafficking without the constraints of clonal selection, allowing researchers to assess aggregate functional consequences of EEA1 ablation in a genetically varied background.
The parental A2780 cell line is an epithelial ovarian carcinoma model established from an untreated patient, retaining wild-type p53 and a hypertriploid karyotype. A2780 cells are cisplatin-sensitive and exhibit robust proliferative and invasive capacities, making them a widely used platform for ovarian cancer biology, drug response profiling, and metastasis research. Their well-characterized genetic and phenotypic features provide a reliable context for investigating the roles of endocytic regulators in cancer cell homeostasis.
EEA1 functions as a key effector of Rab5 GTPase on early endosomes, where it is recruited via its FYVE domain that binds phosphatidylinositol 3-phosphate (PI3P). As a tethering factor, EEA1 mediates homotypic endosome fusion by facilitating SNARE complex assembly, interacting with syntaxin 6, syntaxin 13, and VAMP4. EEA1 operates downstream of growth factor receptors such as EGFR and is regulated by PI3K-mediated PI3P production. Through these interactions, EEA1 orchestrates endosomal maturation, receptor sorting, and downstream signaling attenuation, linking membrane dynamics to cell proliferation and survival pathways.
In the A2780 ovarian carcinoma background, disruption of EEA1 expression is predicted to impair early endosome fusion and cargo trafficking, potentially altering the recycling and degradation of critical receptors including EGFR. This perturbation may influence downstream proliferative signaling, apoptotic thresholds, and drug sensitivity, particularly to cisplatin. Consequently, this knockout model provides a valuable tool for dissecting how endocytic dysregulation contributes to ovarian cancer progression, chemoresistance, and the maintenance of malignant phenotypes.
Key research applications include high-content screening for endocytic regulators, detailed analysis of receptor trafficking via transferrin uptake and immunofluorescence assays, and functional assessment by proliferation and drug sensitivity testing. The polyclonal population is also suited for co-immunoprecipitation and western blotting to evaluate EEA1-interacting partners and downstream signaling alterations. This model supports investigations into endosomal trafficking defects in cancer and neurodegeneration. For additional product details or technical support, please contact Ascent Research.
